SEARCH

Current Edition

Volume 4 Issue 2

A World Leader in Naturally Derived Products Discusses Commercial Success and New Innovations

Mr. Darren Alkins CEO at SPL – Scientific Protein Laboratories, speaks with IBI about their continued development in their science and technical expertise to meet …

Continue Reading →
Volume 4 Issue 2

Supporting Mergers and Acquisitions in the Pharmaceutical/Biopharmaceutical Industry

In recent years, we have seen pharmaceutical company megadeals that saw Takeda acquiring Shire for a total value of $81.7 billion, Bristol-Myers Squibb’s acquisition of …

Continue Reading →
Volume 4 Issue 2

Dealing with the Challenges of Post-translational Modifications (PTMs)

During the structural analysis of recombinant protein biopharmaceutical products, a significant challenge is posed by the issue of Post Translational Modifications (PTMs). This is a …

Continue Reading →
Volume 4 Issue 2

Solving Critical Data Challenges for Chemicallymodified, Biologically-based Therapeutic Candidates

The drug discovery research industry is seeing a growing prevalence of chemically-modified, biologically-based therapeutic candidates. This trend creates urgent and novel challenges for data management …

Continue Reading →
Volume 4 Issue 2

Using Lentiviral Vectors to Advance the Development of Therapeutic Vaccines

Traditionally, vaccination has been used as a preventative strategy, aimed at curbing the impact of a wide range of infectious diseases. Over the past three …

Continue Reading →
Volume 4 Issue 2

Antibody-drug Conjugates: A Trojan Horse Story

According to the World Health Organization, cancer is responsible for 10 million deaths per year, and it is considered as the second leading cause of …

Continue Reading →
Volume 4 Issue 2

Adapting Your Preclinical Animal Model Strategies for a New World

Investigators in the commercial and non-profit sectors have always faced pressure to accelerate their work while balancing the need for quality and the realities of …

Continue Reading →
Volume 4 Issue 2

Standard vs. Hybrid FIH Trials: Advantages and Challenges

First in human (FIH) studies are the key translational studies from preclinical to further clinical development processes. The goal of FIH studies is to investigate …

Continue Reading →
Volume 4 Issue 2

Intricacies and Future Considerations for the Cell and Gene Therapy Cold Chain

The rapidly growing field of cell and gene therapy is both exciting and confusing to many, including those who work in the medical community and …

Continue Reading →
Volume 4 Issue 2

Four Factors for a Biopharmaceutical Manufacturer to Consider when Developing and Managing a Single-use Supply Chain

Single-use technologies are becoming widely utilised in the biopharmaceutical industry for the benefit of offering a more flexible, cost-effective approach to cGMP manufacturing. Single-use technologies …

Continue Reading →
Volume 4 Issue 2

H96: Combining Freeze-drying and High-pressure Homogenisation for Ultra-fine Nanocrystal Production

In recent years, nanomedicine has proven to be key in overcoming many of the challenges associated with poorly water-soluble drugs. Decreasing the size of drug …

Continue Reading →
Volume 4 Issue 2

Data-rich Processing – The Growing Necessity of R&D to GMP Manufacture

Improved diagnosis is driving precision in treatment, accompanied by increasing regulation stringencies from the likes of the MHRA and FDA. This ensures processes, as well …

Continue Reading →
Volume 4 Issue 2

Land Use Change and the Global Pandemic

While medical research has found the path to lead us slowly but steadily out of the current pandemic, the strategies to prevent such pandemics from …

Continue Reading →